Monopar Therapeutics Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 4 - Capital Stock (Details Textual)

Note 4 - Capital Stock (Details Textual)				9 Months Ended
Note 4 - Capital Stock (Details Textual)	Sep. 24, 2025 USD ($) $ / shares shares	Aug. 12, 2024 shares	Aug. 05, 2024 shares	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 23, 2025	Dec. 31, 2024 $ / shares shares	Dec. 23, 2024 $ / shares shares	Jun. 30, 2024 shares	Mar. 31, 2022 shares	Apr. 30, 2020 shares	Oct. 31, 2017 shares	Apr. 30, 2016 shares
Common Stock, Shares Authorized (in shares)				40,000,000			40,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares				$ 0.001			$ 0.001
Common Stock, Shares, Outstanding (in shares)				6,662,930			6,102,560
Proceeds from Issuance of Common Stock \| $				$ 0	$ 3,192,618
Payments for Repurchase of Common Stock \| $				$ 34,999,957	$ (0)
Share Purchase Agreement With Tactic Pharma [Member]
Payments for Repurchase of Common Stock \| $	$ 35,000,000
Stock Repurchased During Period, Shares (in shares)	550,229
Shares Acquired, Average Cost Per Share (in dollars per share) \| $ / shares	$ 63.6098
Tactic Pharma, LLC [Member] \| Monopar Therapeutics [Member]
Ownership Percentage						13.40%
Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								882,761
Class of Pre-Warrant or Right, Price Per Share (in dollars per share) \| $ / shares								$ 23.789
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 0.001
Class of Pre-Warrant or Right, Number, Securities Purchase Agreement (in shares)								882,761
Class of Pre-Warrant or Right, Maximum Beneficial Ownership Percentage							9.99%	9.99%
Class of Warrant or Right, Maximum Beneficial Ownership Percentage				19.99%
Class of Warrant or Right, Outstanding (in shares)				1,843,303
Class of Warrant or Right, Issued (in shares)				960,542			882,761
Capital on Demand Sales Agreement [Member] \| JonesTrading Institutional Services LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)					509,061
Shares Issued, Price Per Share (in dollars per share) \| $ / shares					$ 6.45
Proceeds from Issuance of Common Stock \| $					$ 3,194,310
Payments of Stock Issuance Costs \| $					$ 81,932
Underwriting Agreement [Member]
Shares Issued, Price Per Share (in dollars per share) \| $ / shares								$ 23.79
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,034,433
Shares Issued, Price Per Share (in dollars per share) \| $ / shares	$ 67.67
Proceeds from Issuance of Common Stock \| $	$ 70,000,000
Proceeds from Issuance or Sale of Equity \| $	126,900,000
Proceeds from Issuance of Common Stock, Net \| $	65,800,000
Proceeds from (Repurchase of) Equity \| $	$ 91,900,000
Public Offering [Member] \| Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	960,542
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 0.001
Class of Warrant or Right, Price per Warrant (in dollars per share) \| $ / shares	$ 67.669
Proceeds from Issuance of Warrants \| $	$ 65,000,000
Proceeds from Issuance of Warrants, Net \| $	$ 61,100,000
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		1,420,000	7,100,000						5,100,000	1,020,000	620,000	320,000	140,000
Common Stock, Shares, Outstanding (in shares)		3,520,427							17,601,827
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] \| Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		5	5